FDA accepts Cempra's application for next-gen pneumonia treatment
Prabhavathi Fernandes, the CEO of Chapel Hill-based drug developer Cempra (Nasdaq: CEMP) will circle Dec. 27 and Dec. 28 with a big red marker on her calendar. Those are the deadlines for the U.S. Food and Drug Administration to rule on Cempra’s application for approval for a next-generation pneumonia treatment.
The FDA accepted Cempra’s applications for solithromycin, which Cempra has given the name Solithera, a treatment for treatment for community-acquired bacterial pneumonia (CABP) that…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Jason deBruyn Source Type: news
More News: Bacterial Pneumonia | Biotechnology | Food and Drug Administration (FDA) | Health | Health Management | Pneumonia